Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Radiotherapy and Concurrent Temozolomide in Newly Diagnosed Glioblastoma
NCT02805179Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Sep 2016
- Primary completion
- Feb 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Overall Survival at 12 Months and Median Overall Survival. Started Sep 2016; status: completed.
Beyond the preview
Go deeper on NCT02805179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02805179.